Skip to main content

Clinical Trials Using Durvalumab

Review the clinical trials studying durvalumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 81

Adding an Immunotherapy Drug, MEDI4736 (durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Status: Active
Location: 557 locations
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 460 locations
Immunotherapy after Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Status: Active
Location: 279 locations
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Status: Active
Location: 221 locations
Testing Immunotherapy with or without Stereotactic Body Radiation Therapy in Patients with Advanced Liver Cancer, HELIO-RT Trial
Status: Active
Location: 167 locations
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Status: Active
Location: 205 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 44 locations
Testing the Combination of an Anti-cancer Drug, Iadademstat, with Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Status: Active
Location: 43 locations
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer
Status: Active
Location: 25 locations
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Status: Active
Location: 23 locations
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 20 locations
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Status: Active
Location: 18 locations
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Status: Active
Location: 17 locations
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Status: Active
Location: 14 locations
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Status: Active
Location: 13 locations
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Status: Active
Location: 12 locations
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Status: Active
Location: 9 locations
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Status: Active
Location: 11 locations
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Status: Active
Location: 9 locations
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Status: Active
Location: 8 locations
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Status: Active
Location: 8 locations
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Status: Active
Location: 11 locations
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Status: Active
Location: 8 locations
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Status: Active
Location: 5 locations
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Status: Active
Location: 5 locations